MedTrace Logo

Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.

NCT04622111 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2021-08-18

No results posted yet for this study

Summary

The planned study is to determine the safety and pharmacokinetic properties of CPL207280 compound after single and multiple (two weeks) administration in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

CPL207280

IMP is a tablet with CPL207280 as an Active Pharmaceutical Ingredient (API).

DRUG

Placebo

matching placebo tablet

DRUG

Metformin hydrochloride 750 mg

IMP is a tablet with Metformin hydrochloride as an Active Pharmaceutical Ingredient (API).

Sponsors & Collaborators

  • National Center for Research and Development, Poland

    collaborator OTHER

  • Celon Pharma SA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-27
Primary Completion
2021-04-01
Completion
2021-05-05

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04622111 on ClinicalTrials.gov